Praziquantel - 50 Years of Research

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Parasitology

Background:

• Praziquantel (PZQ) has been the primary treatment for schistosomiasis for fifty years.
• PZQ is also utilized in veterinary medicine combined with antinematode drugs.
• The Schistosoma mansoni TRPM_PZQ channel is identified as the main target of PZQ.

Purpose of the Study:

• To provide an overview of PZQ synthesis routes, including racemic and (R)-PZQ.
• To highlight the ongoing development of pure (R)-PZQ for human application by the Pediatric Praziquantel Consortium.
• To explore the potential for designing next-generation PZQ derivatives based on binding pocket knowledge.

Main Methods:

• Review of existing literature on PZQ synthesis and its mechanism of action.
• Discussion of the discovery of the Sm.TRPM_PZQ channel as the PZQ target.
• Exploration of structure-activity relationships for PZQ derivatives.

Main Results:

• Racemic PZQ is currently used in human and veterinary medicine.
• (R)-PZQ is under development for pediatric use, with potential for improved efficacy.
• Understanding the PZQ binding site in Sm.TRPM_PZQ facilitates rational drug design.

Conclusions:

• The Sm.TRPM_PZQ channel is a validated target for PZQ.
• Further research into PZQ derivatives and related targets like Fasciola hepatica TRPM_PZQ is warranted.
• Development of (R)-PZQ promises enhanced therapeutic options for schistosomiasis.